New clarification platform delivers robust, accelerated performance across multiple mAb processes
Pall Corporation's Stax mAx clarification platform.
The Stax mAx, a single-use harvesting platform, minimizes the impact of process variability between batches.
Pall Corporation has introduced the Stax mAx clarification platform - a robust solution for the economic clarification of monoclonal antibody cell cultures without centrifugation or process additives. The single-use harvesting platform features a 4-layer concept, and has been optimized to maintain performance as cell density and viability change to minimize the impact of process variability between batches. Media configurations are available in many formats to scale directly from bench-top testing up to large-scale clinical production.
“As cell densities increase, demand has grown for less challenging, more economical — both footprint and cost-wise — clarification solutions,” said Mario Philips, Vice President and General Manager of Pall Life Sciences. “The Stax mAx clarification platform was born from Pall’s legacy strength in filtration, and leverages our proven Stax single-use capsule system. This latest addition to our portfolio, once again, reflects our commitment to delivering innovative total solutions to our customers.”
The pre-selected 4-layer, 2 stage platform features sequentially finer grades to remove aggregates, whole cells and cell debris. Constructed to retain a small footprint across a wide range of feed streams (with cell densities of up 35 x 106 cells/mL, and feed turbidities of up to around 3,000 NTU), the Stax mAx clarification platform is scalable to support 1,000 to 2,000 L cell culture volumes.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...